Clinical Overview: Cyletzo, a Biosimilar Version of Adalimumab
July 19th 2022Indications for adalimumab include ankylosing spondylitis, Crohn disease, chronic plaque psoriasis, juvenile idiopathic arthritis, moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Read More
2 Commerce Drive
Cranbury, NJ 08512